Abstract
Objective: Unusual or unexpected effect of treatment Background: Short-course hepatitis C (HCV) treatment with direct-acting antivirals (DAA) under 8 weeks in duration has re-sulted in variable efficacy rates in HCV mono-infection. Further, DAA courses under 8 weeks in duration have not been studied in HIV/HCV co-infection. We present a case report of 12-week sustained virologic suppression after treatment interruption of ledipasvir/sofosbuvir at 4 weeks in a patient with HIV/HCV co-infection. Case Report: A 28-year-old male patient diagnosed with well-controlled HIV infection and HCV co-infection (treatment-naïve, genotype 1a, unknown hepatic fibrosis) started a 12-week course of ledipasvir/sofosbuvir (LDV/SOF) for HCV treatment. The patient completed only 4 weeks of LDV/SOF before returning for follow-up 7 weeks after initi-ation. Ledipasvir/sofosbuvir treatment was discontinued. Sustained virologic suppression at 12 weeks was ob-served after completion of a short, 4-week course of LDV/SOF. Conclusions: Compared to currently recommended treatment durations, clinical trials of short-course DAA treatments of less than 8 weeks have not demonstrated successful rates of SVR12. However, in cases of DAA interruption or in-complete treatment, clinicians may choose to assess for SVR12 prior to continuing or restarting the full treatment course.
Original language | English (US) |
---|---|
Article number | e923326 |
Journal | American Journal of Case Reports |
Volume | 21 |
DOIs | |
State | Published - 2020 |
Keywords
- Antiviral Agents
- HIV Infections
- Hepatitis C
ASJC Scopus subject areas
- General Medicine